SERPINB2 and prostate carcinoma: Additional data demonstrated that 213Bi-PAI2 did not specifically kill the uPA-negative LN3 prostate cancer cell line, supporting the fact that the 213Bi-PAI2 conjugate does not target or destroy tissue that does not express uPA.